-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Jusn5Qibn9+Wg8BkNnuR5TDyJJ+12g/96MxaeLyRMbkQSlIYXxZjx8PaSLLCKB3e BWOxj3np700aLqO2erx32A== 0000914121-98-000255.txt : 19980402 0000914121-98-000255.hdr.sgml : 19980402 ACCESSION NUMBER: 0000914121-98-000255 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19971231 FILED AS OF DATE: 19980401 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: OXIGENE INC CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: SEC FILE NUMBER: 000-21990 FILM NUMBER: 98584980 BUSINESS ADDRESS: STREET 1: 110 EAST 59TH ST CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 2124310001 MAIL ADDRESS: STREET 1: C/O BATTLE FOWLER LLP STREET 2: 75 EAST 55TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 NT 10-K 1 COVER LETTER March 31, 1998 VIA EDGAR - --------- Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: OXiGENE, Inc. - Form 12b-25, Notification of Late Filing of Form 10-K for the period ended December 31, 1997 ----------------------------------------------------------------- Ladies and Gentlemen: On behalf of OXiGENE, Inc. (the "Company"), we hereby file Form 12b-25 in order to extend the time for filing of the Company's Annual Report on Form 10-K for the period ended December 31, 1997. Simultaneously with this filing, we also are sending a copy of this Form 12b-25 to The Nasdaq Stock Market, Inc. Please telephone the undersigned at (212) 504-6804 if you have any questions or comments. Very truly yours, /s/ M. Andica Kunst -------------------------- M. Andica Kunst cc: OXiGENE, Inc. The Nasdaq Stock Market, Inc. EX-99.1 2 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING - ---------------------------- OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 1997 Estimated average burden hours per response.....2.50 - ---------------------------- - ----------------- SEC FILE NUMBER 0-21990 - ----------------- - ----------------- CUSIP NUMBER 691828-10-7 - ----------------- (Check One): /X/Form 10-K /_/Form 20-F /_/Form 11-K /_/Form 10-Q /_/Form N-SAR For Period Ended: December 31, 1997 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended:------------------------------------ - -------------------------------------------------------------------------------- Read Attached Instruction Sheet Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. - -------------------------------------------------------------------------------- If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: - -------------------------------------------------------------------------------- PART I -- REGISTRANT INFORMATION OXiGENE, Inc. - -------------------------------------------------------------------------------- Full Name of Registrant - -------------------------------------------------------------------------------- Former Name if Applicable One Copley Place, Suite 602 - -------------------------------------------------------------------------------- Address of Principal Executive Office (Street and Number) Boston, MA 02116 - -------------------------------------------------------------------------------- City, State and Zip Code PART II -- RULES 12b-25(b) AND (c) If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) (a) the reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; (b) The subject annual report, semi-annual report, transition report on From 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on /X/ or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. PART III -- NARRATIVE State below in reasonable detail the reasons why Form 10-K and Form 10-KSB, 20-F, 11-K, 10-Q Form 10-QSB, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period. All information necessary to complete the filing has not yet been compiled. (Attach Extra Sheets if Needed) SEC 1344 (6/94) PART IV -- OTHER INFORMATION (1) Name and telephone number of person to contact in regard to this notification Gerald A. Eppner (212) 504-6286 ---------------------------- --------------- -------------------- (Name) (Area Code) (Telephone Number) (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). /X/ Yes /_/ No (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? /_/ Yes /X/ No If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. - -------------------------------------------------------------------------------- OXiGENE, Inc. ----------------------------------------------------------------- (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date March 27, 1998 By /s/ Bo A. Haglund --------------------------------------- ------------------------------- Title: Chief Financial Officer -----END PRIVACY-ENHANCED MESSAGE-----